HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection.

Abstract
Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition. The purpose of this study is to determine whether statin and DP could enhance stroke protection through nitric oxide (NO)-dependent vascular effects. Mice were pretreated with DP (10 to 60 mg/kg, q 12 h, 3 days) alone or in combination with a statin (simvastatin; 0.1 to 20 mg/kg per day, 14 days) before transient intraluminal middle cerebral artery occlusion. Although simvastatin (1 mg/kg per day, 14 days) increased endothelial NO synthase (eNOS) activity by 25% and DP (30 mg/kg, q12 h, 3 days) increased aortic cGMP levels by 55%, neither statin nor DP alone, at these subtherapeutic doses, increased absolute cerebral blood flow (CBF) or conferred stroke protection. However, the combination of subtherapeutic doses of simvastatin and DP increased CBF by 50%, decreased stroke volume by 54%, and improved neurologic motor deficits, all of which were absent in eNOS-deficient mice. In contrast, treatment with aspirin (10 mg/kg per day, 3 days) did not augment the neuroprotective effects of DP and/or simvastatin. These findings indicate that statin and DP exert additive NO-dependent vascular effects and suggest that the combination of statin and DP has greater benefits in stroke protection than statin alone through vascular protection.
AuthorsHyung-Hwan Kim, Naoki Sawada, Guray Soydan, Ho-Seong Lee, Zhipeng Zhou, Seo-Kyoung Hwang, Christian Waeber, Michael A Moskowitz, James K Liao
JournalJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (J Cereb Blood Flow Metab) Vol. 28 Issue 7 Pg. 1285-93 (Jul 2008) ISSN: 1559-7016 [Electronic] United States
PMID18382469 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Nitric Oxide
  • Dipyridamole
  • Simvastatin
  • Nitric Oxide Synthase Type III
Topics
  • Animals
  • Cerebrovascular Circulation (drug effects)
  • Dipyridamole (administration & dosage, pharmacology)
  • Drug Synergism
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology)
  • Mice
  • Nitric Oxide (biosynthesis)
  • Nitric Oxide Synthase Type III (deficiency, genetics)
  • Regional Blood Flow (drug effects)
  • Simvastatin (administration & dosage, pharmacology)
  • Stroke (prevention & control)
  • Up-Regulation (drug effects, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: